secwatch.observer — SEC 8-K summary
======================================

Issuer:     AtriCure, Inc. (ATRC)
CIK:        0001323885
Form:       8-K
Filed at:   2023-07-25T23:59:59+00:00
Accession:  0001323885-23-000094
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AtriCure Q2 revenue $100.9M (+19.4% YoY); net loss narrows to $5.1M, adjusted EBITDA positive $8.0M
--------------------------------------------------------------------------------

- Worldwide revenue $100.9M, up 19.4% YoY; U.S. $84.9M (+19.1%), international $16.0M (+20.7%).
- Net loss of $5.1M, improvement of $9.7M vs Q2 2022; EPS loss $0.11 vs $0.32.
- Gross margin 76.4%, up 130 bps YoY; adjusted EBITDA positive $8.0M, up from -$3.2M.
- FY 2023 guidance: revenue $392M-$395M (19-20% growth), adjusted EBITDA ~$12M positive.
- Adjusted loss per share guided at $0.92-$0.94 for full year 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1323885/000132388523000094/0001323885-23-000094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1323885/000132388523000094/atrc-20230725.htm
  HTML page:      https://secwatch.observer/filing/0001323885-23-000094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer